1
Craig Esser, William Hagmann, William Hoffman, Shrenik Shah, Kenny Wong, Renee Chabin, Ravindra Guthikonda, Malcolm Maccoss, Charles Caldwell, Philippe Durette: Substituted 2-aminopyridines as inhibitors of nitric oxide synthase. Merck & Co, Richard C Billups, Curtis C Panzer, David L Rose, October 26, 1999: US05972975 (23 worldwide citation)

Substituted 2-aminopyridine compounds of Formula (I) and pharmaceutically acceptable salts which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders. ##STR1##


2
James Doherty, Conrad Dorn, Philippe Durette, Paul Finke, Malcolm Maccoss, Sander Mills, Shrenik Shah, Soumya Sahoo, William Hagmann, Scott Polo: Substituted azetidinones as anti-inflammatory and antidegenerative agents. Merck & Co, J Antonio Garcia Rivas, Valerie J Camara, Mark R Daniel, September 14, 1999: US05952321 (18 worldwide citation)

New substituted azetidinones of the general Formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described, wherein n is


3
Philippe L Durette, Craig K Esser, William Hagmann, Ihor E Kopka: 15-substituted 4-azasteroids. Merck & Co, Joanne M Giesser, Melvin Winokur, Paul D Matukaitis, October 25, 1994: US05359071 (14 worldwide citation)

Compounds of the formula ##STR1## or a pharmaceutically acceptable salt or ester thereof, wherein R.sup.1 is selected from the group consisting of hydrogen and C.sub.1-10 alkyl;


4

5
Donald W Graham, Susan D Aster, William Hagmann, Richard L Tolman: 17-ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5A-reductase inhibitors. Merck & Co, Joanne M Giesser, Catherine D Fitch, Melvin Winokur, April 23, 1996: US05510485 (13 worldwide citation)

Described are new 17.beta.-ester, amide and ketone 4-aza-5a-androstan-3-ones and related compounds and their use as 5a-reductase inhibitors for treatment of benign prostatic hyperplasia and other hyperandrogenetic related disorders.


6
William Hagmann, Charles G Caldwell, Paul R Gooley: Substituted cyclic derivatives as novel antidegenerative agents. Merck & Co, Curtis C Panzer, David L Rose, Robert J North, April 4, 1995: US05403952 (5 worldwide citation)

Novel substituted cyclic compounds of Formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophic ep ...


7
Kevin Chapman, William Hagmann, Philippe Durette, Craig Esser, Ihor Kopka, Charles Caldwell: Carboxy-peptidyl derivatives as antidegenerative active agents. Merck & Co, Curtis C Panzer, David L Rose, September 30, 1997: US05672583 (4 worldwide citation)

Novel Carboxy-peptidyl compounds of Formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic ep ...


8
Ravindra Guthikonda, William Hagmann, Malcolm Maccoss, Shrenik Shah, Philippe Durette: Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase. Merck & Co, Richard C Billups, David L Rose, Curtis C Panzer, June 1, 1999: US05908842 (4 worldwide citation)

Substituted 2-acylaminopyridine compounds and pharmaceutically acceptable salts which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders.


9

10
William Hagmann, Ihor Kopka: N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents. Merck & Co, Curtis C Panzer, David L Rose, May 13, 1997: US05629343 (2 worldwide citation)

Novel N-(mercaptoacyl)peptidyl compounds are useful as inhibitors of matrix metalloendoproteinases which degrade major components of articular cartilage and basement membranes causing degenerative diseases such as arthritis, periodontal disease, corneal ulceration, are described. For example, N-(2-t ...